Lung Cancer Clinical Trial

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

Summary

The purpose of this study is to collect samples to evaluate the ProGRP and NSE assays independently as aids for monitoring the course of disease and therapy in subjects diagnosed with SCLC.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥ 18
Confirmed diagnosis of SCLC or mixed SCLC/non-SCLC per histopathology results
Scheduled to undergo first-, second- or third-line treatment for SCLC, including chemotherapy, chemotherapy + radiation therapy, or combined concurrent chemoradiotherapy.
Able to understand and willing to provide Informed Consent

Exclusion Criteria:

No diagnosis of SCLC
Not scheduled to undergo treatment for the diagnosis of SCLC
Unable to provide Informed Consent

Study is for people with:

Lung Cancer

Estimated Enrollment:

4

Study ID:

NCT01591512

Recruitment Status:

Terminated

Sponsor:

Fujirebio Diagnostics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Kelly Family Medical Center, PC
Eastpointe Michigan, 48021, United States
St.Louis Cancer Care, LLP
Bridgeton Missouri, 63044, United States
Heartland Regional Medical Center
St. Joseph Missouri, 64506, United States
Hematology Oncology Consultants, Inc.
St. Louis Missouri, 63136, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

4

Study ID:

NCT01591512

Recruitment Status:

Terminated

Sponsor:


Fujirebio Diagnostics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider